Östör, Andrew http://orcid.org/0000-0002-7929-4827
Van den Bosch, Filip
Papp, Kim http://orcid.org/0000-0001-9557-3642
Asnal, Cecilia
Blanco, Ricardo http://orcid.org/0000-0003-2344-2285
Aelion, Jacob http://orcid.org/0000-0001-5727-7199
Carter, Kyle
Stakias, Vassilis
Lippe, Ralph
Drogaris, Leonidas
Soliman, Ahmed M.
Chen, Michael M.
Padilla, Byron
Kivitz, Alan http://orcid.org/0000-0002-1045-1310
Article History
Received: 28 November 2023
Accepted: 14 February 2024
First Online: 18 March 2024
Declarations
:
: Andrew Östör has received speaker or consulting fees and/or research grants from AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. Filip Van den Bosch has received speaker and/or consulting fees from AbbVie, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. Kim Papp has received research funds from AbbVie, Aceleryn, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. He is a consultant for AbbVie, Aceleryn, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Dermavant, Forward Pharma, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, Takeda, and UCB. He is a speaker for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB. He is a committee member for PSOLAR (Psoriasis Longitudinal Assessment and Registry) and PURE (registry of patients with moderate-to-severe chronic plaque psoriasis in Latin America and Canada). Cecilia Asnal has received honoraria or fees for serving on advisory boards or as a speaker, as well as research support from AbbVie, Amgen, Genentech, Janssen, Lilly, Pfizer, Roche, and R-Pharm. Ricardo Blanco has received grants or research support from AbbVie, Merck, and Roche. He has received consultation fees or honoraria for serving as a speaker for AbbVie, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer and Roche. Jacob Aelion has received grants or research support from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galapagos/Gilead, Genentech, GlaxoSmithKline, Lilly, Mallinckrodt, Nektar Therapeutics, Nichi-Iko, Novartis, Pfizer, Regeneron, Roche, Sanofi, Selecta Biosciences, and UCB. Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, and Byron Padilla are full-time employees of AbbVie and may hold AbbVie stock or stock options or AbbVie patents. Alan Kivitz has received consulting fees from Horizon, Frescenius Kabi, Pfizer, GlaxoSmithKline, Janssen, Selecta, Genzyme, Gilead, Synact, Takeda, and Grunenthal; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GlaxoSmithKline, Eli Lilly, Pfizer, AbbVie, Amgen, and UCB; has served on boards or advisory boards for Horizon, Janssen, Chemocentryx, Princeton Biopartners, UCB, and Novartis; and has stock or stock options in Pfizer, GSK, Gilead, Novartis, and Amgen.
: The independent ethics committee or institutional review board (see Supplemental Table InternalRef removed) at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent at screening.